Phase 4 N=25 Geodon in Weight Loss Study for Bipolar Disorders
Bipolar Disorder
Primary: The Primary Outcome Measure Was Weight Change From Baseline to Endpoint. — -9.8 Pounds — p=<0.00001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=88 'Levonorgestrel IUD Insertion After D&E Procedure
Contraceptive Usage
Primary: The Primary Outcome is LNG-IUD Usage Six Months Following Enrollment. — 85.2; 62.9 percentage of participants — p=0.05
Phase 4 N=13 Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan
Hypophosphatasia
Primary: Number of Participants With Adverse Events (AEs) Including Injection Site Reactions (ISRs) and Injection Associated Reactions (IARs) — 9; 2; 0 Participants
Phase 4 N=177 Drug Therapy for Generalized Anxiety Disorder Among the Elderly
Anxiety Disorders · Generalized Anxiety Disorder
Primary: Response Using Clinical Global Impressions-Improvement Scale (CGI-I) — 51; 69 participants
Phase 4 N=55 Tdap Vaccine in Post-Partum Women
Diphtheria · Pertussis · Tetanus
Primary: Geometric Mean Fold Rise in Serum Immunoglobulin G (IgG) by ELISA at Week 2 — 4.8; 8.6; 21.6; 22.4 Fold Rise
Phase 4 N=54 Effectiveness of Triple Therapy With Palonosetron for PON Prophylaxis
Postoperative Nausea and Vomiting
Primary: PONV Incidence — 12 participants
Phase 4 N=60 A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Objective Response Rate (ORR) — 50 percentage of participants
Phase 4 N=102 A Double Blind Study Comparing Hyaluronic Acid, Corticosteroid and Placebo During Arthrocentesis for Temporomandibular Joint (TMJ) Dysfunction
Temporomandibular Joint Dysfunction · Pain · Arthrocentesis
Primary: Change in Pain Between Baseline and Month 1 Scores — -1.1; -1.7; -2.6; -2.0 units on a scale
Phase 4 N=72 Memantine and Cognitive Dysfunction in Bipolar Disorder
Bipolar Disorder
Primary: California Verbal Learning Test (CVLT) at Week 12 — 11.88; 11.55; 11.63; 11.73 correct items
Phase 4 N=70 Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China
HEMOPHILIA B
Primary: Percentage of Participants Who Developed Factor IX Inhibitor — 3.3; 0.0; 0.0; 1.8 percentage of participants
Phase 4 N=45 Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery
Chronic Sinusitis
Primary: To Estimate the Change in Bleeding Category (Surgical Field Improvement) as Measured on a Six-point Scale, Measured From 0 (Best Case) to 5 (Worst Case). — 2.17; 2.04…
Phase 4 N=72 Efficacy and Safety of Galantamine for Improving Dysfunction in People With Bipolar Disorder
Bipolar Disorder
Primary: Scores on the California Verbal Learning Test (CVLT-II) at Screening and Week 16 — 50.15; 47.21; 58.88; 52.90 number of total words remembered
Phase 4 N=47 Vortioxetine for Menopausal Depression
Depression · Menopause · Vasomotor Disturbance
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale Score (MADRS) at Week 8 (Visit 5) — -22.8 units on a scale
Phase 4 N=24,081 Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen
Arthritis, Rheumatoid
Primary: The First Occurrence of Antiplatelet Trialists Collaboration (APTC) Composite Endpoint, Confirmed by the Clinical Events Committee (CEC). — 2.3; 2.7; 2.5; 1.7 Percentage…
Phase 4 N=96 Postpartum Etonogestrel Implant for Adolescents
Adolescence · Contraception · Postpartum
Primary: Continuation at 1 Year — 21; 30 participants